Mereo Biopharma Group PLC
NASDAQ:MREO
Mereo Biopharma Group PLC
Long-Term Debt
Mereo Biopharma Group PLC
Long-Term Debt Peer Comparison
Competitive Long-Term Debt Analysis
Latest Figures & CAGR of Competitors
Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Mereo Biopharma Group PLC
NASDAQ:MREO
|
Long-Term Debt
£1.2m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Long-Term Debt
$75.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Long-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Long-Term Debt
$30.8m
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Long-Term Debt
£48m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Long-Term Debt
£273.6m
|
CAGR 3-Years
30%
|
CAGR 5-Years
21%
|
CAGR 10-Years
12%
|
See Also
What is Mereo Biopharma Group PLC's Long-Term Debt?
Long-Term Debt
1.2m
GBP
Based on the financial report for Dec 31, 2022, Mereo Biopharma Group PLC's Long-Term Debt amounts to 1.2m GBP.
What is Mereo Biopharma Group PLC's Long-Term Debt growth rate?
Long-Term Debt CAGR 3Y
-57%
Over the last year, the Long-Term Debt growth was -93%. The average annual Long-Term Debt growth rates for Mereo Biopharma Group PLC have been -57% over the past three years .